Timothy Lopez, MD
Hematology & Oncology · Santa Fe, NMNPI 1174521983
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.2% of the total across 118 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in NM, where the typical reported total is $2,649.
Across 118 payments — averaging $21.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$370
- Pfizer$214
- Novartis$205
- AbbVie$197
- Exelixis Inc.$188
- Servier Pharmaceuticals LLC$176
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,41995%
- Education$1235%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 17 | $370 |
| Pfizer | 7 | $214 |
| Novartis | 10 | $205 |
| AbbVie | 10 | $197 |
| Exelixis Inc. | 9 | $188 |
| Servier Pharmaceuticals LLC | 8 | $176 |
| Karyopharm Therapeutics Inc. | 1 | $122 |
| Johnson & Johnson | 5 | $122 |
| E.r. Squibb & Sons, L.L.C. | 4 | $80 |
| Merck | 4 | $77 |
| AstraZeneca | 4 | $77 |
| Mirati Therapeutics, Inc. | 4 | $76 |
| Array Biopharma Inc | 5 | $75 |
| EMD Serono, Inc. | 3 | $69 |
| GSK | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Seagen Inc. | 3 | $46 |
| Stemline Therapeutics Inc. | 2 | $42 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $27 |
| Adaptive Biotechnologies Corporation | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Agios Pharmaceuticals, Inc. | 1 | $22 |
| Bristol Myers Squibb | 1 | $21 |
| Sanofi | 1 | $21 |
| Beigene USA, Inc. | 1 | $19 |
| Spectrum Pharmaceuticals Inc. | 1 | $18 |
| Amgen | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Pharmaessentia USA Corporation | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Tempus AI, Inc | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Taiho Oncology, Inc. | 1 | $13 |
| Acrotech Biopharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XPOVIO$122
How this compares
$2,542 in reported general payments places this provider in the 45th percentile of 54 hematology & oncology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 85 | $1,221,533 |
| CalquenceAcalabrutinib Maleate | 36 | $541,379 |
| RevlimidLenalidomide | 20 | $351,555 |
| EliquisApixaban | 20 | $19,397 |
| XareltoRivaroxaban | 14 | $19,366 |
| Abiraterone Acetate | 19 | $17,371 |
| Anastrozole | 54 | $1,023 |
| Tamoxifen Citrate | 11 | $550 |
| Hydroxyurea | 19 | $505 |
| Dexamethasone | 15 | $283 |
| Acyclovir | 18 | $236 |
| Tamsulosin Hcl | 17 | $229 |
| Prochlorperazine Maleate | 11 | $197 |
| Esomeprazole Magnesium | 11 | $166 |
| Prednisone | 26 | $144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada, Xarelto | $122 | $1,240,89999 claims |
| AstraZenecaCalquence | $77 | $541,37936 claims |
| Bristol Myers SquibbRevlimid | $21 | $351,55520 claims |
| PfizerEliquis | $214 | $19,39720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 54 hematology & oncology providers in New Mexico.
Other hematology & oncology in Santa Fe
- David SnyderSanta Fe$13K
- Kathryn ChanSanta Fe$11K
- Karen LorussoSanta Fe$6K
- Ursa Brown GlabermanAlbuquerque$219K
- Neda Hashemi SadraeiAlbuquerque$96K
- Muhammad TarakjiAlbuquerque$34K
- Yara AbdouAlbuquerque$25K
- Sardar ImamFarmington$24K
- George AtwehAlbuquerque$24K
- Ankit AnandFarmington$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.